List JF - Search Results

1

Targeting renal glucose reabsorption for the treatment of type 2 diabetes mellitus using the SGLT2 inhibitor dapagliflozin.

Jabbour SA, Whaley JM, Tirmenstein M, Poucher SM, Reilly TP, Boulton DW, Saye J, List JF, Parikh S. Jabbour SA, et al. Among authors: list jf. Postgrad Med. 2012 Jul;124(4):62-73. doi: 10.3810/pgm.2012.07.2569. Postgrad Med. 2012. PMID: 22913895 Review.

2

Effects of dapagliflozin on cardiovascular risk factors.

Ptaszynska A, Hardy E, Johnsson E, Parikh S, List J. Ptaszynska A, et al. Postgrad Med. 2013 May;125(3):181-9. doi: 10.3810/pgm.2013.05.2667. Postgrad Med. 2013. PMID: 23748519 Review.

3

Inhibition of SGLT2: a novel strategy for treatment of type 2 diabetes mellitus.

Pfister M, Whaley JM, Zhang L, List JF. Pfister M, et al. Among authors: list jf. Clin Pharmacol Ther. 2011 Apr;89(4):621-5. doi: 10.1038/clpt.2011.16. Epub 2011 Feb 23. Clin Pharmacol Ther. 2011. PMID: 21346749 Review. No abstract available.

4

Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus.

Whaley JM, Tirmenstein M, Reilly TP, Poucher SM, Saye J, Parikh S, List JF. Whaley JM, et al. Among authors: list jf. Diabetes Metab Syndr Obes. 2012;5:135-48. doi: 10.2147/DMSO.S22503. Epub 2012 Jul 23. Diabetes Metab Syndr Obes. 2012. PMID: 22923998 Free PMC article.

5

Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans.

List JF, Whaley JM. List JF, et al. Kidney Int Suppl. 2011 Mar;(120):S20-7. doi: 10.1038/ki.2010.512. Kidney Int Suppl. 2011. PMID: 21358698 Free article. Review.

6

Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria.

Geerlings S, Fonseca V, Castro-Diaz D, List J, Parikh S. Geerlings S, et al. Diabetes Res Clin Pract. 2014 Mar;103(3):373-81. doi: 10.1016/j.diabres.2013.12.052. Epub 2014 Jan 8. Diabetes Res Clin Pract. 2014. PMID: 24529566 Free article. Review.

7

Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin.

Johnsson KM, Ptaszynska A, Schmitz B, Sugg J, Parikh SJ, List JF. Johnsson KM, et al. Among authors: list jf. J Diabetes Complications. 2013 Sep-Oct;27(5):479-84. doi: 10.1016/j.jdiacomp.2013.04.012. Epub 2013 Jun 24. J Diabetes Complications. 2013. PMID: 23806570

8

Urinary tract infections in patients with diabetes treated with dapagliflozin.

Johnsson KM, Ptaszynska A, Schmitz B, Sugg J, Parikh SJ, List JF. Johnsson KM, et al. Among authors: list jf. J Diabetes Complications. 2013 Sep-Oct;27(5):473-8. doi: 10.1016/j.jdiacomp.2013.05.004. Epub 2013 Jul 10. J Diabetes Complications. 2013. PMID: 23849632

9

Safety profile of dapagliflozin for type 2 diabetes: pooled analysis of clinical studies for overall safety and rare events.

Ptaszynska A, Johnsson KM, Parikh SJ, de Bruin TW, Apanovitch AM, List JF. Ptaszynska A, et al. Among authors: list jf. Drug Saf. 2014 Oct;37(10):815-29. doi: 10.1007/s40264-014-0213-4. Drug Saf. 2014. PMID: 25096959

10

Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy.

Rosenstock J, Vico M, Wei L, Salsali A, List JF. Rosenstock J, et al. Among authors: list jf. Diabetes Care. 2012 Jul;35(7):1473-8. doi: 10.2337/dc11-1693. Epub 2012 Mar 23. Diabetes Care. 2012. PMID: 22446170 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

40 results

Search Page

Filters